Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 5, 2011, Pages 350-353

  Özkan, Hasan ^a   Erdal, Harun ^a   Koçak, Erdem ^b   Tutkak, Hüseyin ^a   Karaeren, Zihni ^a   Yakut, Mustafa ^a   Köklü, Seyfettin ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

fetoprotein; Glypican 3; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; WILSON DISEASE;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GLYPICANS; HEPATITIS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052844270     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20484     Document Type: Article

References (19)

1. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 1971;4:408.
2. Schwartz JM, Larson AM, Gold PJ, et al. Hepatocellular carcinoma: A one-year experience at a tertiary referral center in the United States (abstract). Hepatology 1999;30:278A.
3. Gallo C, Perrone F, Placido S, et al. Cancer of the liver Italian program (CLIP) investigators: A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998;28:751.
4. Filmus J, Selleck SB. Glypicans: Proteoglycans with a surprise. J Clin Invest 2001;108:497-501.
5. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
6. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-1767.
7. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441.
8. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
9. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
10. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:1405-1411.
11. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology 2002;122:1609-1619.
12. Jtso W. Serum alpha-fetoprotein and its lectin reactivity in liver diseases: A review. Ann Clin Lab Sci 1990;20:98-105.
13. Collier, J, Sherman, M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273.
14. Lok AS, Lai CLSO. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110-115.
15. Chen DS, Sung JL, Sheu JC, et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984;86:1404-1409.
16. Gonzalez AD, Kaya M, Shi W, et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 1998;141:1407-1414.
17. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-7412.
18. Komtong S, Mahachai V, Kongtawelert P, Tangkijvanich P. The diagnostic role of serum glypican-3 in hepatolcellular carcinoma. Thailand J Gastroenterol 2007;8:51-56.
19. Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010;25:129-137.